Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to -$3.07.

  • Tarsus Pharmaceuticals' EPS (Weighted Average and Diluted) rose 50.82% to -$0.30 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.01, marking a year-over-year increase of 46.68%. This contributed to the annual value of -$3.07 for FY2024, which is 33.55% up from last year.
  • Tarsus Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$3.07 in FY2024, which was up 33.55% from -$4.62 recorded in FY2023.
  • Tarsus Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.67 during FY2021, with a 5-year trough of -$4.62 in FY2023.
  • Over the past 3 years, Tarsus Pharmaceuticals' median EPS (Weighted Average and Diluted) value was -$3.07 (recorded in 2024), while the average stood at -$3.40.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first spiked by 84.49% in 2021, then slumped by 276.12% in 2022.
  • Tarsus Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$4.32 in 2020, then soared by 84.49% to -$0.67 in 2021, then tumbled by 276.12% to -$2.52 in 2022, then tumbled by 83.33% to -$4.62 in 2023, then surged by 33.55% to -$3.07 in 2024.